nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—PTGS2—Etoposide—sarcoma	0.143	0.542	CbGbCtD
Tolmetin—PTGS1—Etoposide—sarcoma	0.121	0.458	CbGbCtD
Tolmetin—TDO2—mammary gland—sarcoma	0.0292	0.119	CbGeAlD
Tolmetin—PTGS2—periosteum—sarcoma	0.0144	0.0585	CbGeAlD
Tolmetin—MPO—endothelium—sarcoma	0.0117	0.0476	CbGeAlD
Tolmetin—PTGS2—leg—sarcoma	0.0115	0.0467	CbGeAlD
Tolmetin—CXCL8—myometrium—sarcoma	0.0114	0.0466	CbGeAlD
Tolmetin—PTGS2—hindlimb—sarcoma	0.0102	0.0417	CbGeAlD
Tolmetin—PTGS2—cartilage tissue—sarcoma	0.0101	0.041	CbGeAlD
Tolmetin—TDO2—liver—sarcoma	0.00923	0.0376	CbGeAlD
Tolmetin—PTGS2—appendage—sarcoma	0.00877	0.0358	CbGeAlD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—EZR—sarcoma	0.00875	0.0401	CbGpPWpGaD
Tolmetin—CXCL8—smooth muscle tissue—sarcoma	0.00864	0.0352	CbGeAlD
Tolmetin—TDO2—lymph node—sarcoma	0.00708	0.0288	CbGeAlD
Tolmetin—CXCL8—bone marrow—sarcoma	0.00629	0.0256	CbGeAlD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—sarcoma	0.00609	0.028	CbGpPWpGaD
Tolmetin—MPO—Vitamin B12 Metabolism—HBA1—sarcoma	0.00603	0.0277	CbGpPWpGaD
Tolmetin—MPO—hematopoietic system—sarcoma	0.00574	0.0234	CbGeAlD
Tolmetin—PTGS1—endothelium—sarcoma	0.00554	0.0226	CbGeAlD
Tolmetin—MPO—connective tissue—sarcoma	0.00552	0.0225	CbGeAlD
Tolmetin—CXCL8—testis—sarcoma	0.00538	0.0219	CbGeAlD
Tolmetin—PTGS2—endothelium—sarcoma	0.0053	0.0216	CbGeAlD
Tolmetin—CXCL8—liver—sarcoma	0.00508	0.0207	CbGeAlD
Tolmetin—MPO—skin of body—sarcoma	0.00499	0.0203	CbGeAlD
Tolmetin—Proteinuria—Mitoxantrone—sarcoma	0.00494	0.0181	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—HBA1—sarcoma	0.00491	0.0225	CbGpPWpGaD
Tolmetin—MPO—C-MYB transcription factor network—CD34—sarcoma	0.00488	0.0224	CbGpPWpGaD
Tolmetin—MPO—C-MYB transcription factor network—MYOD1—sarcoma	0.00488	0.0224	CbGpPWpGaD
Tolmetin—Protein urine present—Mitoxantrone—sarcoma	0.00487	0.0179	CcSEcCtD
Tolmetin—Blood urea increased—Thiotepa—sarcoma	0.00475	0.0174	CcSEcCtD
Tolmetin—TDO2—Tryptophan metabolism—MDM2—sarcoma	0.00453	0.0208	CbGpPWpGaD
Tolmetin—Blood urea increased—Mitoxantrone—sarcoma	0.0041	0.015	CcSEcCtD
Tolmetin—MPO—lymphoid tissue—sarcoma	0.00404	0.0165	CbGeAlD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—TLE1—sarcoma	0.00402	0.0184	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—HBA1—sarcoma	0.0039	0.0179	CbGpPWpGaD
Tolmetin—CXCL8—lymph node—sarcoma	0.0039	0.0159	CbGeAlD
Tolmetin—PTGS2—S1P1 pathway—PLCG1—sarcoma	0.00369	0.0169	CbGpPWpGaD
Tolmetin—MPO—bone marrow—sarcoma	0.00368	0.015	CbGeAlD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—sarcoma	0.0035	0.0161	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Mitoxantrone—sarcoma	0.00348	0.0128	CcSEcCtD
Tolmetin—CXCL8—Chemokine receptors bind chemokines—CXCR4—sarcoma	0.0034	0.0156	CbGpPWpGaD
Tolmetin—Toxic epidermal necrolysis—Dactinomycin—sarcoma	0.00326	0.012	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Mitoxantrone—sarcoma	0.00326	0.012	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—PLCG1—sarcoma	0.00318	0.0146	CbGpPWpGaD
Tolmetin—Gastrointestinal haemorrhage—Mitoxantrone—sarcoma	0.00315	0.0116	CcSEcCtD
Tolmetin—MPO—testis—sarcoma	0.00314	0.0128	CbGeAlD
Tolmetin—PTGS2—myometrium—sarcoma	0.00303	0.0123	CbGeAlD
Tolmetin—MPO—liver—sarcoma	0.00297	0.0121	CbGeAlD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.00297	0.0136	CbGpPWpGaD
Tolmetin—Dysuria—Thiotepa—sarcoma	0.00295	0.0108	CcSEcCtD
Tolmetin—PTGS2—embryo—sarcoma	0.00291	0.0119	CbGeAlD
Tolmetin—Cardiac failure congestive—Etoposide—sarcoma	0.00289	0.0106	CcSEcCtD
Tolmetin—Weight increased—Thiotepa—sarcoma	0.00287	0.0105	CcSEcCtD
Tolmetin—PTGS1—seminal vesicle—sarcoma	0.00286	0.0117	CbGeAlD
Tolmetin—Renal failure—Thiotepa—sarcoma	0.00277	0.0101	CcSEcCtD
Tolmetin—Stomatitis—Thiotepa—sarcoma	0.00274	0.0101	CcSEcCtD
Tolmetin—PTGS2—seminal vesicle—sarcoma	0.00274	0.0112	CbGeAlD
Tolmetin—Stomatitis—Dactinomycin—sarcoma	0.00272	0.00999	CcSEcCtD
Tolmetin—PTGS1—hematopoietic system—sarcoma	0.00272	0.0111	CbGeAlD
Tolmetin—Anaphylactoid reaction—Etoposide—sarcoma	0.00271	0.00994	CcSEcCtD
Tolmetin—Haematuria—Thiotepa—sarcoma	0.00268	0.00984	CcSEcCtD
Tolmetin—Epistaxis—Thiotepa—sarcoma	0.00265	0.00974	CcSEcCtD
Tolmetin—Agranulocytosis—Thiotepa—sarcoma	0.00263	0.00963	CcSEcCtD
Tolmetin—PTGS1—connective tissue—sarcoma	0.00262	0.0107	CbGeAlD
Tolmetin—Dysuria—Vincristine—sarcoma	0.00262	0.0096	CcSEcCtD
Tolmetin—PTGS2—S1P1 pathway—PDGFRB—sarcoma	0.00261	0.012	CbGpPWpGaD
Tolmetin—Agranulocytosis—Dactinomycin—sarcoma	0.00261	0.00956	CcSEcCtD
Tolmetin—PTGS2—hematopoietic system—sarcoma	0.0026	0.0106	CbGeAlD
Tolmetin—CXCL8—Syndecan-3-mediated signaling events—SRC—sarcoma	0.00258	0.0118	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—IL2—sarcoma	0.00253	0.0116	CbGpPWpGaD
Tolmetin—Weight decreased—Vincristine—sarcoma	0.00253	0.00929	CcSEcCtD
Tolmetin—Hepatitis—Dactinomycin—sarcoma	0.00251	0.0092	CcSEcCtD
Tolmetin—PTGS2—connective tissue—sarcoma	0.0025	0.0102	CbGeAlD
Tolmetin—Weight increased—Mitoxantrone—sarcoma	0.00248	0.0091	CcSEcCtD
Tolmetin—Weight decreased—Mitoxantrone—sarcoma	0.00247	0.00905	CcSEcCtD
Tolmetin—Stomatitis—Vincristine—sarcoma	0.00243	0.00892	CcSEcCtD
Tolmetin—Drowsiness—Mitoxantrone—sarcoma	0.00243	0.00891	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—MDM2—sarcoma	0.00242	0.0111	CbGpPWpGaD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—MMP2—sarcoma	0.00242	0.0111	CbGpPWpGaD
Tolmetin—PTGS1—smooth muscle tissue—sarcoma	0.0024	0.00977	CbGeAlD
Tolmetin—Renal failure—Mitoxantrone—sarcoma	0.00239	0.00876	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—PLCG1—sarcoma	0.00238	0.0109	CbGpPWpGaD
Tolmetin—Erythema multiforme—Dactinomycin—sarcoma	0.00237	0.0087	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—PDGFRA—sarcoma	0.00237	0.0109	CbGpPWpGaD
Tolmetin—Stomatitis—Mitoxantrone—sarcoma	0.00237	0.00869	CcSEcCtD
Tolmetin—PTGS1—skin of body—sarcoma	0.00237	0.00964	CbGeAlD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—sarcoma	0.00237	0.0109	CbGpPWpGaD
Tolmetin—Urinary tract infection—Mitoxantrone—sarcoma	0.00236	0.00866	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Etoposide—sarcoma	0.00236	0.00866	CcSEcCtD
Tolmetin—Tinnitus—Thiotepa—sarcoma	0.00235	0.00864	CcSEcCtD
Tolmetin—Haematuria—Mitoxantrone—sarcoma	0.00232	0.0085	CcSEcCtD
Tolmetin—PTGS2—smooth muscle tissue—sarcoma	0.00229	0.00934	CbGeAlD
Tolmetin—MPO—lymph node—sarcoma	0.00228	0.00929	CbGeAlD
Tolmetin—Agranulocytosis—Mitoxantrone—sarcoma	0.00227	0.00832	CcSEcCtD
Tolmetin—PTGS2—skin of body—sarcoma	0.00226	0.00922	CbGeAlD
Tolmetin—CXCL8—Syndecan-3-mediated signaling events—EGFR—sarcoma	0.00226	0.0104	CbGpPWpGaD
Tolmetin—Glossitis—Epirubicin—sarcoma	0.0022	0.00806	CcSEcCtD
Tolmetin—Hepatitis—Mitoxantrone—sarcoma	0.00218	0.008	CcSEcCtD
Tolmetin—PTGS2—S1P1 pathway—KDR—sarcoma	0.00216	0.00992	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.00215	0.00985	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—CCND1—sarcoma	0.00211	0.00968	CbGpPWpGaD
Tolmetin—PTGS1—cardiac atrium—sarcoma	0.00207	0.00842	CbGeAlD
Tolmetin—PTGS1—uterus—sarcoma	0.00206	0.00838	CbGeAlD
Tolmetin—Glossitis—Doxorubicin—sarcoma	0.00203	0.00746	CcSEcCtD
Tolmetin—Renal failure—Etoposide—sarcoma	0.00199	0.00729	CcSEcCtD
Tolmetin—Stomatitis—Etoposide—sarcoma	0.00197	0.00723	CcSEcCtD
Tolmetin—PTGS2—uterus—sarcoma	0.00196	0.00801	CbGeAlD
Tolmetin—Blood urea increased—Epirubicin—sarcoma	0.00191	0.00701	CcSEcCtD
Tolmetin—Agranulocytosis—Etoposide—sarcoma	0.00189	0.00692	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—PDGFRA—sarcoma	0.00188	0.00861	CbGpPWpGaD
Tolmetin—MPO—C-MYB transcription factor network—KIT—sarcoma	0.00187	0.00857	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—VEGFA—sarcoma	0.00184	0.00844	CbGpPWpGaD
Tolmetin—PTGS2—lymphoid tissue—sarcoma	0.00183	0.00746	CbGeAlD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—sarcoma	0.00183	0.0084	CbGpPWpGaD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—JUN—sarcoma	0.00183	0.00838	CbGpPWpGaD
Tolmetin—PTGS1—tendon—sarcoma	0.0018	0.00734	CbGeAlD
Tolmetin—Oedema—Dactinomycin—sarcoma	0.00178	0.00653	CcSEcCtD
Tolmetin—Blood urea increased—Doxorubicin—sarcoma	0.00177	0.00649	CcSEcCtD
Tolmetin—Thrombocytopenia—Thiotepa—sarcoma	0.00176	0.00645	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—CREB1—sarcoma	0.00175	0.00803	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Dactinomycin—sarcoma	0.00174	0.0064	CcSEcCtD
Tolmetin—Lymphadenopathy—Epirubicin—sarcoma	0.00172	0.00632	CcSEcCtD
Tolmetin—PTGS2—tendon—sarcoma	0.00172	0.00702	CbGeAlD
Tolmetin—Erythema multiforme—Etoposide—sarcoma	0.00172	0.00629	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—MYC—sarcoma	0.00169	0.00776	CbGpPWpGaD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—SRC—sarcoma	0.00168	0.00769	CbGpPWpGaD
Tolmetin—PTGS2—bone marrow—sarcoma	0.00167	0.00679	CbGeAlD
Tolmetin—CXCL8—Bladder Cancer—EGFR—sarcoma	0.00165	0.00759	CbGpPWpGaD
Tolmetin—Vascular purpura—Epirubicin—sarcoma	0.00164	0.00603	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—MMP2—sarcoma	0.00163	0.00747	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Epirubicin—sarcoma	0.00162	0.00595	CcSEcCtD
Tolmetin—Chest pain—Mitoxantrone—sarcoma	0.00162	0.00593	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IGF1R—sarcoma	0.0016	0.00733	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—HBA1—sarcoma	0.0016	0.00732	CbGpPWpGaD
Tolmetin—Somnolence—Thiotepa—sarcoma	0.0016	0.00585	CcSEcCtD
Tolmetin—Lymphadenopathy—Doxorubicin—sarcoma	0.00159	0.00585	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—IL2—sarcoma	0.00159	0.00731	CbGpPWpGaD
Tolmetin—Anaphylactic shock—Vincristine—sarcoma	0.00159	0.00584	CcSEcCtD
Tolmetin—Oedema—Vincristine—sarcoma	0.00159	0.00584	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—MYOD1—sarcoma	0.00159	0.00728	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—CD34—sarcoma	0.00159	0.00728	CbGpPWpGaD
Tolmetin—Dyspepsia—Thiotepa—sarcoma	0.00158	0.0058	CcSEcCtD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.00157	0.00718	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Vincristine—sarcoma	0.00156	0.00572	CcSEcCtD
Tolmetin—Anaphylactic shock—Mitoxantrone—sarcoma	0.00155	0.00569	CcSEcCtD
Tolmetin—Oedema—Mitoxantrone—sarcoma	0.00155	0.00569	CcSEcCtD
Tolmetin—Constipation—Thiotepa—sarcoma	0.00153	0.00563	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—MMP2—sarcoma	0.00153	0.007	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—CREB1—sarcoma	0.00153	0.007	CbGpPWpGaD
Tolmetin—Purpura—Epirubicin—sarcoma	0.00153	0.0056	CcSEcCtD
Tolmetin—Vascular purpura—Doxorubicin—sarcoma	0.00152	0.00558	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Epirubicin—sarcoma	0.00152	0.00557	CcSEcCtD
Tolmetin—Thrombocytopenia—Mitoxantrone—sarcoma	0.00152	0.00557	CcSEcCtD
Tolmetin—Cardiac failure congestive—Doxorubicin—sarcoma	0.0015	0.0055	CcSEcCtD
Tolmetin—PTGS1—testis—sarcoma	0.00149	0.00608	CbGeAlD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.00148	0.00677	CbGpPWpGaD
Tolmetin—Gastrointestinal haemorrhage—Epirubicin—sarcoma	0.00147	0.00539	CcSEcCtD
Tolmetin—Gastrointestinal pain—Thiotepa—sarcoma	0.00147	0.00538	CcSEcCtD
Tolmetin—CXCL8—IL-3 Signaling Pathway—JUN—sarcoma	0.00146	0.0067	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Dactinomycin—sarcoma	0.00146	0.00534	CcSEcCtD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.00144	0.00659	CbGpPWpGaD
Tolmetin—Urticaria—Thiotepa—sarcoma	0.00143	0.00523	CcSEcCtD
Tolmetin—Body temperature increased—Thiotepa—sarcoma	0.00142	0.0052	CcSEcCtD
Tolmetin—Abdominal pain—Thiotepa—sarcoma	0.00142	0.0052	CcSEcCtD
Tolmetin—Purpura—Doxorubicin—sarcoma	0.00141	0.00518	CcSEcCtD
Tolmetin—Abdominal pain—Dactinomycin—sarcoma	0.00141	0.00517	CcSEcCtD
Tolmetin—Body temperature increased—Dactinomycin—sarcoma	0.00141	0.00517	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Doxorubicin—sarcoma	0.00141	0.00516	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—TP53—sarcoma	0.00139	0.00638	CbGpPWpGaD
Tolmetin—Somnolence—Mitoxantrone—sarcoma	0.00138	0.00505	CcSEcCtD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.00137	0.00627	CbGpPWpGaD
Tolmetin—Dyspepsia—Mitoxantrone—sarcoma	0.00136	0.005	CcSEcCtD
Tolmetin—Constipation—Vincristine—sarcoma	0.00136	0.00499	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.00136	0.00499	CcSEcCtD
Tolmetin—CXCL8—TSLP Signaling Pathway—SRC—sarcoma	0.00135	0.00621	CbGpPWpGaD
Tolmetin—PTGS2—liver—sarcoma	0.00135	0.00549	CbGeAlD
Tolmetin—Chest pain—Etoposide—sarcoma	0.00134	0.00493	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—CREB1—sarcoma	0.00134	0.00617	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—HRAS—sarcoma	0.00133	0.0061	CbGpPWpGaD
Tolmetin—Constipation—Mitoxantrone—sarcoma	0.00132	0.00486	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.00132	0.00486	CcSEcCtD
Tolmetin—CXCL8—IL-3 Signaling Pathway—SRC—sarcoma	0.00131	0.00601	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Vincristine—sarcoma	0.0013	0.00477	CcSEcCtD
Tolmetin—Gastritis—Epirubicin—sarcoma	0.0013	0.00477	CcSEcCtD
Tolmetin—Anaphylactic shock—Etoposide—sarcoma	0.00129	0.00473	CcSEcCtD
Tolmetin—Asthenia—Thiotepa—sarcoma	0.00129	0.00472	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—CCND1—sarcoma	0.00128	0.00588	CbGpPWpGaD
Tolmetin—CXCL8—Peptide ligand-binding receptors—CXCR4—sarcoma	0.00128	0.00588	CbGpPWpGaD
Tolmetin—Asthenia—Dactinomycin—sarcoma	0.00128	0.00469	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	0.00128	0.00586	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00127	0.00465	CcSEcCtD
Tolmetin—PTGS2—Selenium Micronutrient Network—HBA1—sarcoma	0.00127	0.00581	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Etoposide—sarcoma	0.00126	0.00463	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—CCND1—sarcoma	0.00126	0.00578	CbGpPWpGaD
Tolmetin—CXCL8—ATF-2 transcription factor network—JUN—sarcoma	0.00126	0.00577	CbGpPWpGaD
Tolmetin—Abdominal pain—Vincristine—sarcoma	0.00126	0.00461	CcSEcCtD
Tolmetin—Body temperature increased—Vincristine—sarcoma	0.00126	0.00461	CcSEcCtD
Tolmetin—Urticaria—Mitoxantrone—sarcoma	0.00123	0.00452	CcSEcCtD
Tolmetin—Diarrhoea—Thiotepa—sarcoma	0.00123	0.0045	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—CREB1—sarcoma	0.00123	0.00562	CbGpPWpGaD
Tolmetin—Abdominal pain—Mitoxantrone—sarcoma	0.00122	0.00449	CcSEcCtD
Tolmetin—Body temperature increased—Mitoxantrone—sarcoma	0.00122	0.00449	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.00122	0.00449	CcSEcCtD
Tolmetin—Diarrhoea—Dactinomycin—sarcoma	0.00122	0.00447	CcSEcCtD
Tolmetin—CXCL8—TSLP Signaling Pathway—MYC—sarcoma	0.00121	0.00556	CbGpPWpGaD
Tolmetin—Gastritis—Doxorubicin—sarcoma	0.0012	0.00442	CcSEcCtD
Tolmetin—PTGS2—S1P1 pathway—VEGFA—sarcoma	0.00119	0.00547	CbGpPWpGaD
Tolmetin—Dysuria—Epirubicin—sarcoma	0.00119	0.00436	CcSEcCtD
Tolmetin—Dizziness—Thiotepa—sarcoma	0.00119	0.00435	CcSEcCtD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—HRAS—sarcoma	0.00118	0.00541	CbGpPWpGaD
Tolmetin—CXCL8—LPA receptor mediated events—JUN—sarcoma	0.00118	0.00541	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.00116	0.00534	CbGpPWpGaD
Tolmetin—Weight increased—Epirubicin—sarcoma	0.00116	0.00424	CcSEcCtD
Tolmetin—Weight decreased—Epirubicin—sarcoma	0.00115	0.00422	CcSEcCtD
Tolmetin—Somnolence—Etoposide—sarcoma	0.00115	0.0042	CcSEcCtD
Tolmetin—Asthenia—Vincristine—sarcoma	0.00114	0.00419	CcSEcCtD
Tolmetin—Vomiting—Thiotepa—sarcoma	0.00114	0.00419	CcSEcCtD
Tolmetin—Drowsiness—Epirubicin—sarcoma	0.00113	0.00416	CcSEcCtD
Tolmetin—Vomiting—Dactinomycin—sarcoma	0.00113	0.00415	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—IL2—sarcoma	0.00113	0.00517	CbGpPWpGaD
Tolmetin—Headache—Thiotepa—sarcoma	0.00112	0.00412	CcSEcCtD
Tolmetin—Renal failure—Epirubicin—sarcoma	0.00111	0.00409	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—MDM2—sarcoma	0.00111	0.0051	CbGpPWpGaD
Tolmetin—Asthenia—Mitoxantrone—sarcoma	0.00111	0.00408	CcSEcCtD
Tolmetin—Stomatitis—Epirubicin—sarcoma	0.0011	0.00405	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—NRAS—sarcoma	0.0011	0.00506	CbGpPWpGaD
Tolmetin—Constipation—Etoposide—sarcoma	0.0011	0.00404	CcSEcCtD
Tolmetin—Urinary tract infection—Epirubicin—sarcoma	0.0011	0.00404	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—CCND1—sarcoma	0.0011	0.00504	CbGpPWpGaD
Tolmetin—Dysuria—Doxorubicin—sarcoma	0.0011	0.00403	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—JUN—sarcoma	0.0011	0.00503	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—CTNNB1—sarcoma	0.00109	0.005	CbGpPWpGaD
Tolmetin—Diarrhoea—Vincristine—sarcoma	0.00109	0.00399	CcSEcCtD
Tolmetin—PTGS1—lymph node—sarcoma	0.00108	0.0044	CbGeAlD
Tolmetin—CXCL8—G alpha (i) signalling events—CXCR4—sarcoma	0.00108	0.00496	CbGpPWpGaD
Tolmetin—Haematuria—Epirubicin—sarcoma	0.00108	0.00396	CcSEcCtD
Tolmetin—Weight increased—Doxorubicin—sarcoma	0.00107	0.00393	CcSEcCtD
Tolmetin—Epistaxis—Epirubicin—sarcoma	0.00107	0.00392	CcSEcCtD
Tolmetin—Nausea—Thiotepa—sarcoma	0.00107	0.00391	CcSEcCtD
Tolmetin—Weight decreased—Doxorubicin—sarcoma	0.00106	0.0039	CcSEcCtD
Tolmetin—Diarrhoea—Mitoxantrone—sarcoma	0.00106	0.00389	CcSEcCtD
Tolmetin—Nausea—Dactinomycin—sarcoma	0.00106	0.00388	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—SRC—sarcoma	0.00106	0.00485	CbGpPWpGaD
Tolmetin—Agranulocytosis—Epirubicin—sarcoma	0.00106	0.00388	CcSEcCtD
Tolmetin—Gastrointestinal pain—Etoposide—sarcoma	0.00105	0.00387	CcSEcCtD
Tolmetin—Dizziness—Vincristine—sarcoma	0.00105	0.00386	CcSEcCtD
Tolmetin—Drowsiness—Doxorubicin—sarcoma	0.00105	0.00385	CcSEcCtD
Tolmetin—PTGS2—lymph node—sarcoma	0.00103	0.00421	CbGeAlD
Tolmetin—Renal failure—Doxorubicin—sarcoma	0.00103	0.00378	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—MYC—sarcoma	0.00103	0.00472	CbGpPWpGaD
Tolmetin—Urticaria—Etoposide—sarcoma	0.00102	0.00376	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—IL2—sarcoma	0.00102	0.0047	CbGpPWpGaD
Tolmetin—MPO—Folate Metabolism—TP53—sarcoma	0.00102	0.0047	CbGpPWpGaD
Tolmetin—Stomatitis—Doxorubicin—sarcoma	0.00102	0.00375	CcSEcCtD
Tolmetin—Abdominal pain—Etoposide—sarcoma	0.00102	0.00374	CcSEcCtD
Tolmetin—Body temperature increased—Etoposide—sarcoma	0.00102	0.00374	CcSEcCtD
Tolmetin—Urinary tract infection—Doxorubicin—sarcoma	0.00102	0.00374	CcSEcCtD
Tolmetin—Hepatitis—Epirubicin—sarcoma	0.00102	0.00373	CcSEcCtD
Tolmetin—Vomiting—Vincristine—sarcoma	0.00101	0.00371	CcSEcCtD
Tolmetin—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—sarcoma	0.001	0.00459	CbGpPWpGaD
Tolmetin—Haematuria—Doxorubicin—sarcoma	0.000999	0.00367	CcSEcCtD
Tolmetin—Headache—Vincristine—sarcoma	0.000997	0.00366	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—IL2—sarcoma	0.000994	0.00456	CbGpPWpGaD
Tolmetin—Epistaxis—Doxorubicin—sarcoma	0.000989	0.00363	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.000988	0.00453	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.000986	0.00452	CbGpPWpGaD
Tolmetin—Vomiting—Mitoxantrone—sarcoma	0.000985	0.00361	CcSEcCtD
Tolmetin—Visual impairment—Epirubicin—sarcoma	0.00098	0.0036	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.000978	0.00449	CbGpPWpGaD
Tolmetin—Agranulocytosis—Doxorubicin—sarcoma	0.000978	0.00359	CcSEcCtD
Tolmetin—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—sarcoma	0.000973	0.00446	CbGpPWpGaD
Tolmetin—Headache—Mitoxantrone—sarcoma	0.000971	0.00356	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—JUN—sarcoma	0.000967	0.00444	CbGpPWpGaD
Tolmetin—Erythema multiforme—Epirubicin—sarcoma	0.000961	0.00353	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—KRAS—sarcoma	0.00095	0.00436	CbGpPWpGaD
Tolmetin—Tinnitus—Epirubicin—sarcoma	0.000948	0.00348	CcSEcCtD
Tolmetin—Nausea—Vincristine—sarcoma	0.000945	0.00347	CcSEcCtD
Tolmetin—Hepatitis—Doxorubicin—sarcoma	0.000941	0.00345	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—EGFR—sarcoma	0.000927	0.00425	CbGpPWpGaD
Tolmetin—Asthenia—Etoposide—sarcoma	0.000925	0.00339	CcSEcCtD
Tolmetin—CXCL8—IL-3 Signaling Pathway—HRAS—sarcoma	0.000921	0.00423	CbGpPWpGaD
Tolmetin—Nausea—Mitoxantrone—sarcoma	0.00092	0.00338	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—MDM2—sarcoma	0.000913	0.00419	CbGpPWpGaD
Tolmetin—Visual impairment—Doxorubicin—sarcoma	0.000907	0.00333	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—IL2—sarcoma	0.000906	0.00416	CbGpPWpGaD
Tolmetin—Erythema multiforme—Doxorubicin—sarcoma	0.00089	0.00326	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—MYC—sarcoma	0.000882	0.00405	CbGpPWpGaD
Tolmetin—Diarrhoea—Etoposide—sarcoma	0.000882	0.00324	CcSEcCtD
Tolmetin—Tinnitus—Doxorubicin—sarcoma	0.000877	0.00322	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—CTNNB1—sarcoma	0.000875	0.00401	CbGpPWpGaD
Tolmetin—Flatulence—Epirubicin—sarcoma	0.000872	0.0032	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—VEGFA—sarcoma	0.00087	0.00399	CbGpPWpGaD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000859	0.00394	CbGpPWpGaD
Tolmetin—Dizziness—Etoposide—sarcoma	0.000852	0.00313	CcSEcCtD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000837	0.00384	CbGpPWpGaD
Tolmetin—Vomiting—Etoposide—sarcoma	0.000819	0.00301	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—JUN—sarcoma	0.000812	0.00372	CbGpPWpGaD
Tolmetin—Headache—Etoposide—sarcoma	0.000807	0.00296	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—HRAS—sarcoma	0.000807	0.0037	CbGpPWpGaD
Tolmetin—Flatulence—Doxorubicin—sarcoma	0.000807	0.00296	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000804	0.00369	CbGpPWpGaD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—JUN—sarcoma	0.000793	0.00364	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—JUN—sarcoma	0.000793	0.00364	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	0.000792	0.00364	CbGpPWpGaD
Tolmetin—Nausea—Etoposide—sarcoma	0.000766	0.00281	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000764	0.00351	CbGpPWpGaD
Tolmetin—Chest pain—Epirubicin—sarcoma	0.000754	0.00277	CcSEcCtD
Tolmetin—TDO2—Metabolism—ENO2—sarcoma	0.000747	0.00343	CbGpPWpGaD
Tolmetin—CXCL8—LPA receptor mediated events—HRAS—sarcoma	0.000744	0.00341	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—IL2—sarcoma	0.000743	0.00341	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—HBA1—sarcoma	0.000742	0.00341	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—TP53—sarcoma	0.000724	0.00332	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—CCND1—sarcoma	0.000724	0.00332	CbGpPWpGaD
Tolmetin—Anaphylactic shock—Epirubicin—sarcoma	0.000722	0.00265	CcSEcCtD
Tolmetin—Oedema—Epirubicin—sarcoma	0.000722	0.00265	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—SRC—sarcoma	0.000711	0.00326	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Epirubicin—sarcoma	0.000707	0.0026	CcSEcCtD
Tolmetin—Chest pain—Doxorubicin—sarcoma	0.000697	0.00256	CcSEcCtD
Tolmetin—Oedema—Doxorubicin—sarcoma	0.000668	0.00245	CcSEcCtD
Tolmetin—Anaphylactic shock—Doxorubicin—sarcoma	0.000668	0.00245	CcSEcCtD
Tolmetin—Thrombocytopenia—Doxorubicin—sarcoma	0.000654	0.0024	CcSEcCtD
Tolmetin—CXCL8—GPCR ligand binding—CXCR4—sarcoma	0.000654	0.003	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000647	0.00297	CbGpPWpGaD
Tolmetin—Somnolence—Epirubicin—sarcoma	0.000642	0.00236	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—TP53—sarcoma	0.000638	0.00293	CbGpPWpGaD
Tolmetin—Dyspepsia—Epirubicin—sarcoma	0.000636	0.00233	CcSEcCtD
Tolmetin—TDO2—Metabolism—PLCG1—sarcoma	0.000634	0.00291	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—JUN—sarcoma	0.000634	0.00291	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000629	0.00289	CbGpPWpGaD
Tolmetin—Constipation—Epirubicin—sarcoma	0.000618	0.00227	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—KIT—sarcoma	0.000607	0.00278	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000603	0.00277	CbGpPWpGaD
Tolmetin—Somnolence—Doxorubicin—sarcoma	0.000594	0.00218	CcSEcCtD
Tolmetin—Gastrointestinal pain—Epirubicin—sarcoma	0.000591	0.00217	CcSEcCtD
Tolmetin—Dyspepsia—Doxorubicin—sarcoma	0.000588	0.00216	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000587	0.0027	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—MYC—sarcoma	0.000581	0.00266	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.00058	0.00266	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—JUN—sarcoma	0.000578	0.00265	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—MDM2—sarcoma	0.000578	0.00265	CbGpPWpGaD
Tolmetin—Urticaria—Epirubicin—sarcoma	0.000574	0.00211	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000573	0.00263	CbGpPWpGaD
Tolmetin—Constipation—Doxorubicin—sarcoma	0.000572	0.0021	CcSEcCtD
Tolmetin—Body temperature increased—Epirubicin—sarcoma	0.000571	0.0021	CcSEcCtD
Tolmetin—Abdominal pain—Epirubicin—sarcoma	0.000571	0.0021	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—EGFR—sarcoma	0.000568	0.00261	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000552	0.00253	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Doxorubicin—sarcoma	0.000547	0.00201	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.00054	0.00248	CbGpPWpGaD
Tolmetin—Urticaria—Doxorubicin—sarcoma	0.000531	0.00195	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000529	0.00243	CbGpPWpGaD
Tolmetin—Abdominal pain—Doxorubicin—sarcoma	0.000528	0.00194	CcSEcCtD
Tolmetin—Body temperature increased—Doxorubicin—sarcoma	0.000528	0.00194	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—TP53—sarcoma	0.000524	0.0024	CbGpPWpGaD
Tolmetin—Asthenia—Epirubicin—sarcoma	0.000518	0.0019	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000505	0.00232	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—JUN—sarcoma	0.000502	0.0023	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—HRAS—sarcoma	0.000501	0.0023	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000499	0.00229	CbGpPWpGaD
Tolmetin—Diarrhoea—Epirubicin—sarcoma	0.000494	0.00181	CcSEcCtD
Tolmetin—Asthenia—Doxorubicin—sarcoma	0.00048	0.00176	CcSEcCtD
Tolmetin—Dizziness—Epirubicin—sarcoma	0.000478	0.00175	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—TP53—sarcoma	0.000477	0.00219	CbGpPWpGaD
Tolmetin—Vomiting—Epirubicin—sarcoma	0.000459	0.00169	CcSEcCtD
Tolmetin—Diarrhoea—Doxorubicin—sarcoma	0.000457	0.00168	CcSEcCtD
Tolmetin—Headache—Epirubicin—sarcoma	0.000453	0.00166	CcSEcCtD
Tolmetin—Dizziness—Doxorubicin—sarcoma	0.000442	0.00162	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—MDM2—sarcoma	0.000436	0.002	CbGpPWpGaD
Tolmetin—Nausea—Epirubicin—sarcoma	0.000429	0.00157	CcSEcCtD
Tolmetin—Vomiting—Doxorubicin—sarcoma	0.000425	0.00156	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000424	0.00195	CbGpPWpGaD
Tolmetin—Headache—Doxorubicin—sarcoma	0.000419	0.00154	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	0.000416	0.00191	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000406	0.00186	CbGpPWpGaD
Tolmetin—Nausea—Doxorubicin—sarcoma	0.000397	0.00146	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—JUN—sarcoma	0.000379	0.00174	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—CXCR4—sarcoma	0.00037	0.0017	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	0.000358	0.00164	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—CXCR4—sarcoma	0.000336	0.00154	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—MYC—sarcoma	0.000334	0.00153	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—VEGFA—sarcoma	0.000331	0.00152	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—TP53—sarcoma	0.000331	0.00152	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—IL2—sarcoma	0.000325	0.00149	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—CCND1—sarcoma	0.000317	0.00146	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TLE1—sarcoma	0.000311	0.00143	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	0.000308	0.00142	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000299	0.00137	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VEGFC—sarcoma	0.000263	0.00121	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	0.000262	0.0012	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—MYC—sarcoma	0.000254	0.00117	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—TP53—sarcoma	0.00025	0.00115	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—EGFR—sarcoma	0.000249	0.00114	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000248	0.00114	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—MMP2—sarcoma	0.00023	0.00105	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000216	0.00099	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000215	0.000988	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000214	0.00098	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—FLT1—sarcoma	0.00021	0.000964	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TP53—sarcoma	0.000209	0.000959	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PLCG1—sarcoma	0.000206	0.000947	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CXCR4—sarcoma	0.000198	0.00091	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ATF1—sarcoma	0.000196	0.0009	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TLE1—sarcoma	0.000195	0.000894	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000193	0.000886	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000188	0.000863	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—CREB1—sarcoma	0.00018	0.000825	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—CTNNB1—sarcoma	0.000176	0.000807	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NPM1—sarcoma	0.000176	0.000806	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000173	0.000794	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000169	0.000777	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ENO2—sarcoma	0.000161	0.000737	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.00016	0.000734	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—HBA1—sarcoma	0.00016	0.000732	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IGF1R—sarcoma	0.000154	0.000706	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ENO2—sarcoma	0.000152	0.000698	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—FOXO1—sarcoma	0.000147	0.000672	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—IL2—sarcoma	0.000146	0.000672	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PDGFRB—sarcoma	0.000146	0.000671	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PDGFRA—sarcoma	0.000144	0.000661	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000142	0.000652	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PLCG1—sarcoma	0.000136	0.000625	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—IL2—sarcoma	0.000133	0.00061	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PLCG1—sarcoma	0.000129	0.000593	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ENO2—sarcoma	0.000127	0.000585	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—HBA1—sarcoma	0.000127	0.000581	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CXCR4—sarcoma	0.000124	0.000569	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KDR—sarcoma	0.000121	0.000556	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KIT—sarcoma	0.000112	0.000512	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—NRAS—sarcoma	0.000112	0.000512	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PLCG1—sarcoma	0.000108	0.000496	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CREB1—sarcoma	0.000106	0.000488	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—EGFR—sarcoma	0.000102	0.000467	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—KRAS—sarcoma	9.61e-05	0.000441	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FOXO1—sarcoma	9.17e-05	0.000421	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PDGFRB—sarcoma	9.15e-05	0.00042	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PDGFRA—sarcoma	9.01e-05	0.000413	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MDM2—sarcoma	8.79e-05	0.000403	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—HRAS—sarcoma	8.17e-05	0.000375	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IL2—sarcoma	7.86e-05	0.00036	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CCND1—sarcoma	7.66e-05	0.000351	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—JUN—sarcoma	7.64e-05	0.000351	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CTNNB1—sarcoma	7.58e-05	0.000348	CbGpPWpGaD
Tolmetin—PTGS2—Disease—KIT—sarcoma	6.98e-05	0.00032	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—SRC—sarcoma	6.86e-05	0.000315	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VEGFA—sarcoma	6.68e-05	0.000306	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CREB1—sarcoma	6.65e-05	0.000305	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NRAS—sarcoma	6.59e-05	0.000303	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MYC—sarcoma	6.14e-05	0.000282	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—EGFR—sarcoma	6.01e-05	0.000276	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KRAS—sarcoma	5.68e-05	0.00026	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MDM2—sarcoma	5.5e-05	0.000252	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TP53—sarcoma	5.04e-05	0.000231	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—HRAS—sarcoma	4.82e-05	0.000221	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CTNNB1—sarcoma	4.74e-05	0.000218	CbGpPWpGaD
Tolmetin—PTGS2—Disease—SRC—sarcoma	4.29e-05	0.000197	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NRAS—sarcoma	4.13e-05	0.000189	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MYC—sarcoma	3.84e-05	0.000176	CbGpPWpGaD
Tolmetin—PTGS2—Disease—EGFR—sarcoma	3.76e-05	0.000172	CbGpPWpGaD
Tolmetin—PTGS2—Disease—KRAS—sarcoma	3.55e-05	0.000163	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HRAS—sarcoma	3.02e-05	0.000138	CbGpPWpGaD
